Literature DB >> 24899959

Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131.

Jai Hyuen Lee1, Seok Gun Park1.   

Abstract

PURPOSE: Patients receiving high-dose I-131 to treat differentiated thyroid cancer are isolated from visitors to limit radiation exposure to reasonable levels. The appropriate isolation time is unclear and has not been reported in Korea. The purpose of this study was to estimate the isolation time and investigate the possibility of earlier release from isolation.
METHODS: This study was a retrospective analysis of data from 71 patients (10 men and 61 women; mean age, 49 ± 11.1 y) who received 3.7 GBq (47 patients), 5.55 GBq (23 patients), or 7.4 GBq (1 patient) of I-131 between January 2008 and December 2008. The radiation dose was measured with a fixed probe placed inside the isolation room. The total estimated dose equivalent (TEDE) to family members, the time required for the external dose rate to become <0.07 mSv/h, and the time required for whole-body retention to become <1.2 GBq were calculated.
RESULTS: By the TEDE criterion (<5 mSv), 70 of 71 patients (98.6%) could have been released without isolation. By the external dose rate criterion, 10 of 71 (14.1%) and 60 of 71 patients (84.5%) could have been released without isolation and within 24 h, respectively. With whole-body retention criterion, 19 of 71 (26.8%) and 48 of 71 patients (67.6%) could have been released within 24 h and within 48 h, respectively.
CONCLUSIONS: Appropriate release times were estimated and compared using different criteria. Most patients could have been released without isolation or within 24 h of radiation treatment.

Entities:  

Keywords:  I-131; Radiation protection; Radioisotope therapy; Thyroid cancer

Year:  2010        PMID: 24899959      PMCID: PMC4042923          DOI: 10.1007/s13139-010-0041-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  10 in total

1.  Hospital discharge of patients with thyroid carcinoma treated with 131I.

Authors:  Carlos D Venencia; Alejandro G Germanier; Silvia R Bustos; Andrea A Giovannini; Eduardo P Wyse
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

2.  Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.

Authors:  S F Barrington; A G Kettle; M J O'Doherty; C P Wells; E J Somer; A J Coakley
Journal:  Eur J Nucl Med       Date:  1996-02

3.  Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.

Authors:  F J Rutar; S C Augustine; D Colcher; J A Siegel; D A Jacobson; M A Tempero; V J Dukat; M A Hohenstein; L S Gobar; J M Vose
Journal:  J Nucl Med       Date:  2001-06       Impact factor: 10.057

4.  Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.

Authors:  Massimiliano Pacilio; Luciano Bianciardi; Vincenzo Panichelli; Giovanni Argirò; Cesidio Cipriani
Journal:  Nucl Med Commun       Date:  2005-07       Impact factor: 1.690

5.  Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.

Authors:  G S Pant; S K Sharma; C S Bal; Rakesh Kumar; G K Rath
Journal:  Radiat Prot Dosimetry       Date:  2005-08-16       Impact factor: 0.972

6.  Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131.

Authors:  Milovan D Matovic; Slobodan M Jankovic; Marija Jeremic; Zoran Tasic; Marina Vlajkovic
Journal:  Thyroid       Date:  2009-08       Impact factor: 6.568

7.  Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas.

Authors:  Hahn Wook Kang; Jung Heyun No; Jae Hoon Chung; Yong-Ki Min; Myung-Shik Lee; Moon-Kyu Lee; Jung Hyun Yang; Kwang-Won Kim
Journal:  Thyroid       Date:  2004-01       Impact factor: 6.568

8.  131I effective half-life and dosimetry in thyroid cancer patients.

Authors:  Hervé Remy; Isabelle Borget; Sophie Leboulleux; Nadine Guilabert; Frédéric Lavielle; Jérome Garsi; Claire Bournaud; Séverine Gupta; Martin Schlumberger; Marcel Ricard
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

9.  Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.

Authors:  Pedro Weslley Rosário; Michelle Aparecida Ribeiro Borges; Saulo Purisch
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

10.  Prevalence of thyroid cancer at a medical screening center: pathological features of screen-detected thyroid carcinomas.

Authors:  Yoon Jung Choi; Yong Lai Park; Jang Hyun Koh
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

  10 in total
  1 in total

1.  In vitro evaluation of an iodine radionuclide dosimeter (IRD) for continuous patient monitoring.

Authors:  Sanaz Hariri Tabrizi; Meysam Ramezani; Seyed Amir Hossein Feghhi; Parham Geramifar
Journal:  Med Biol Eng Comput       Date:  2020-01-28       Impact factor: 2.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.